Equities Analysts Issue Forecasts for Geron FY2025 Earnings

Geron Corporation (NASDAQ:GERN) – Equities researchers at Wedbush decreased their FY2025 earnings per share estimates for shares of Geron in a report released on Wednesday, November 5th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will earn ($0.10) per share for the year, down from their previous forecast of ($0.08). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron’s Q4 2025 earnings at ($0.02) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.03) EPS, FY2027 earnings at $0.16 EPS, FY2028 earnings at $0.55 EPS and FY2029 earnings at $0.80 EPS.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group initiated coverage on Geron in a research report on Thursday, July 10th. They issued a “sell” rating and a $1.00 target price on the stock. Needham & Company LLC reduced their price objective on Geron from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Geron has a consensus rating of “Hold” and an average price target of $3.64.

Geron Stock Down 0.9%

GERN stock opened at $1.08 on Friday. Geron has a 52 week low of $1.04 and a 52 week high of $4.50. The company has a quick ratio of 6.79, a current ratio of 7.87 and a debt-to-equity ratio of 0.46. The firm has a 50-day simple moving average of $1.30 and a 200-day simple moving average of $1.36. The stock has a market capitalization of $689.06 million, a P/E ratio of -8.31 and a beta of 0.57.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $47.23 million during the quarter, compared to analyst estimates of $55.24 million. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GERN. Summit X LLC grew its stake in shares of Geron by 43.1% in the 1st quarter. Summit X LLC now owns 547,899 shares of the biopharmaceutical company’s stock valued at $871,000 after buying an additional 164,927 shares during the period. Private Advisor Group LLC raised its position in shares of Geron by 78.5% during the 1st quarter. Private Advisor Group LLC now owns 338,597 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 148,949 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Geron in the first quarter valued at approximately $63,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Geron by 13.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 170,441 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 20,133 shares during the last quarter. Finally, Kazazian Asset Management LLC purchased a new stake in Geron in the first quarter valued at $76,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.